Document:

Exhibit 4.1

 

IMMUNOME,
INC.

 

AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT

 

     

     

    

 

TABLE OF CONTENTS

 

	 	 	Page
	1.	Definitions	1
	2.	Registration Rights	4
	 	2.1	Demand Registration	4
	 	2.2	Piggyback Registration	5
	 	2.3	Underwriting Requirements	6
	 	2.4	Obligations of the Company	7
	 	2.5	Furnish Information	8
	 	2.6	Expenses of Registration	9
	 	2.7	Delay of Registration	9
	 	2.8	Indemnification	9
	 	2.9	Reports Under Exchange Act	11
	 	2.10	Limitations on Subsequent Registration Rights	12
	 	2.11	“Market Standoff” Agreement	12
	 	2.12	Restrictions on Transfer	13
	 	2.13	Termination of Registration Rights	14
	3.	Information and Observer Rights	14
	 	3.1	Delivery of Financial Statements	14
	 	3.2	Inspection	15
	 	3.3	Termination of Information Rights	16
	 	3.4	Confidentiality	16
	4.	Rights to Future Stock Issuances	16
	 	4.1	Right of First Offer	16
	 	4.2	Termination	17
	5.	Additional Covenants	17
	 	5.1	Insurance	17
	 	5.2	Employee Agreements	17
	 	5.3	Employee Stock	17
	 	5.4	Qualified Small Business Stock	17
	 	5.5	Matters Requiring Board Approval	17
	 	5.6	Board Matters	18

 

    -i-

     

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	 	Page
	 	5.7	Successor Indemnification	18
	 	5.8	Indemnification Matters	19
	 	5.9	Termination of Covenants	19
	 	5.10	Harassment Policy	19
	6.	Miscellaneous	20
	 	6.1	Successors and Assigns	20
	 	6.2	Governing Law	20
	 	6.3	Counterparts	20
	 	6.4	Titles and Subtitles	20
	 	6.5	Notices	20
	 	6.6	Amendments and Waivers	21
	 	6.7	Severability	22
	 	6.8	Aggregation of Stock	22
	 	6.9	Additional Investors	22
	 	6.10	Entire Agreement	22
	 	6.11	Waiver of Jury Trial	22
	 	6.12	Arbitration	23
	 	6.13	Delays or Omissions	23
	 	6.14	Schedules	23

 

Schedule A - Investors

 

    -ii-

     

    

 

AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT

 

THIS AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT(this “Agreement”) is made as of June 2, 2020, by and among Immunome, Inc., a Delaware
corporation (the “Company”) and each holder of the Company’s Series A Preferred Stock, $0.0001 par value
per share and any additional series of Preferred Stock of the Company hereafter authorized (together, “Preferred Stock”)
listed on Schedule A (together with any subsequent holders of Preferred Stock and transferees who become parties hereto
as “Investors” pursuant to Section 6.1 or Section 6.9, the “Investors”).

 

Background:

 

A.       The
Company and certain Investors are entering into a Series A Preferred Stock Purchase Agreement, dated as of June 2, 2020 (the “2020
Purchase Agreement”), pursuant to which such Investors will agree to purchase and the Company will agree to sell shares
of Preferred Stock.

 

B.       Certain
of the Investors and the Company are parties to an Investor Rights Agreement dated November 18, 2015 (as amended, the “Original
Agreement”). In order to induce the purchasers to purchase shares of Preferred Stock pursuant to the 2020 Purchase Agreement,
the Company and the Investors are entering into this Agreement to amend and restate the Original Agreement.

 

NOW, THEREFORE, the Company
and the Investors agree as follows:

 

1.                 
Definitions. For purposes of this Agreement:

 

1.1             
“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing
member, officer, director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter
existing which is controlled by one or more general partners, managing members or investment advisers of, or shares the same management
company or investment adviser with, such Person.

 

1.1             
“Board of Directors” means the board of directors of the Company.

 

1.2             
“Certificate” means the Company’s Certificate of Incorporation, as amended and/or restated
from time to time.

 

1.3             
“Common Stock” means shares of the Company’s common stock, par value $0.0001 per share.

 

1.4             
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto
may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim
or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement
of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus
contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact
required to be stated therein, or necessary to make the statements therein not misleading or (iii) any violation or alleged violation
by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law,
or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

     1

     

    

 

1.5             
“Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable
for (in each case, directly or indirectly), Common Stock, including options and warrants.

 

1.6             
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder.

 

1.7             
“Excluded Registration” means (i) a registration relating to the sale or grant of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a
registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the
same information as would be required to be included in a registration statement covering the sale of the Registrable Securities
or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered.

 

1.8             
“Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor
registration form under the Securities Act subsequently adopted by the SEC.

 

1.9             
“Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration
form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by
reference to other documents filed by the Company with the SEC.

 

1.10          
“GAAP” means generally accepted accounting principles in the United States as in effect from time
to time.

 

1.11          
“Holder” means any holder of Registrable Securities who is a party to this Agreement.

 

1.12          
“Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, registered domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law,
including, adoptive relationships, of a natural person referred to herein.

 

1.13          
“Initiating Holders” means, collectively, Holders who properly initiate a registration request under
this Agreement.

 

1.14          
“IPO” means the Company’s first underwritten public offering of its Common Stock under the
Securities Act.

 

     2

     

    

 

 

1.15        
 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates,
holds at least 10% of the shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other
recapitalization or reclassification effected after the date hereof).

 

1.16         
“New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that
are, or may become, convertible or exchangeable into or exercisable for such equity securities.

 

1.17         
“Person” means any individual, corporation, partnership, trust, limited liability company, association
or other entity.

 

1.18         
“Preemptive Rights Holder” means any Investor that, individually or together with such Investor’s
Affiliates, holds at least 5% of the shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination,
or other recapitalization or reclassification effected after the date hereof).

 

1.19         
“Preferred Stock” means shares of the Company’s Preferred Stock, par value $0.0001 per share.

 

1.20         
“Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred
Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise
of any other securities of the Company, acquired by the Investors after the date hereof and (iii) any Common Stock issued as (or
issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution
with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all
cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement
are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration
rights have terminated pursuant to Section 2.13.

 

1.21         
“Registrable Securities then outstanding” means the number of shares determined by adding the number
of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly
or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities.

 

1.22         
“Restricted Securities” means the securities of the Company required to be notated with the legend
set forth in Section 2.12(b).

 

1.23         
“SEC” means the Securities and Exchange Commission.

 

1.24         
“SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

 

1.25         
“SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 

    3

     

    

 

1.26        
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.

 

1.27         
“Selling Expenses” means all underwriting discounts, selling commissions and stock transfer taxes
applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and
disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6.

 

1.28         
“Series A Director” means any director of the Company that the holders of record of the Preferred
Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate.

 

2.                 
Registration Rights. The Company covenants and agrees as follows:

 

2.1             
Demand Registration.

 

(a)              
If at any time 180 days after the effective date of the registration statement for the IPO, the Company receives a request
from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement
with respect to at least 40% of the Registrable Securities then outstanding, then the Company shall (x) within ten days after
the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating
Holders; and (y) as soon as practicable, and in any event within 60 days after the date such request is given by the Initiating
Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating
Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by
any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice
is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3.

 

(b)              
If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders
of at least 20% of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect
to Registrable Securities then outstanding of such Holders having an anticipated aggregate offering price, net of Selling Expenses,
of at least $1 million, then the Company shall (i) within ten days after the date such request is given, give a Demand Notice
to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after the date
such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each
such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations
of Section 2.1(c) and Section 2.3.

 

(c)              
Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment
of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement
to either become effective or remain effective for as long as such registration statement otherwise would be required to remain
effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other
similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona
fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the
Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and
any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than
120 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more
than once in any 12 month period; and provided further that the Company shall not register any securities for its own account
or that of any other stockholder during such 120 day period other than an Excluded Registration.

 

    4

     

    

 

(d)              
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section
2.1 (i) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending
on a date that is 120 days after the effective date of, a Company-initiated registration, provided that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the
Company has effected two registrations pursuant to Section 2.1; or (iii) if the Initiating Holders propose to dispose of
shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section
2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section
2.1(b) (x) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and
ending on a date that is 120 days after the effective date of, a Company-initiated registration, provided that the Company is
actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or
(y) if the Company has effected one registration pursuant to Section 2.1(b) within the 12 month period immediately preceding
the date of such request. A registration shall not be counted as “effected” for purposes of this Section 2.1(d)
until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders
withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to
one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be
counted as “effected” for purposes of this Section 2.1(d); provided, that if such withdrawal is during
a period the Company has deferred taking action pursuant to Section 2.1(c), then the Initiating Holders may withdraw their
request for registration and such registration will not be counted as “effected” for purposes of this Section 2.1(d).

 

2.2            
Piggyback Registration. If the Company proposes to register (including, for this purpose, a registration effected by
the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public
offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly
give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given
by the Company, the Company shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable
Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate
or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether
or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses)
of such withdrawn registration shall be borne by the Company in accordance with Section 2.6.

 

    5

     

    

 

2.3            
Underwriting Requirements.

 

(a)              
If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1,
and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall
be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include
such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in
such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.
All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in
Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting.
Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s) advise(s) the Initiating Holders
in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Company shall so advise
all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities
that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other
proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities
held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded
from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters
may round the number of shares allocated to any Holder to the nearest 100 shares.

 

(b)             
In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section
2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless
the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such
quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company.
If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering
exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine
is compatible with the success of the offering, then the Company shall be required to include in the offering only that number
of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine
will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities
requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering
shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities
owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate
the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares
allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are
first entirely excluded from the offering or (ii) the number of Registrable Securities included in the offering be reduced below
20% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders
may be excluded further if the underwriters make the determination described above and no other stockholder’s securities
are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling
Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members,
stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners,
members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling
Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate
number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.

 

    6

     

    

 

(c)              
For purposes of Section 2.1, a registration shall not be counted as “effected” if, as a result of an
exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than 50% of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included.

 

2.4           
Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable
Securities, the Company shall, as expeditiously as reasonably possible:

 

(a)              
prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially
reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority
of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days
or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that
(i) such 120 day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter
of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the
case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis,
subject to compliance with applicable SEC rules, such 120 day period shall be extended for up to 90 days, if necessary, to keep
the registration statement effective until all such Registrable Securities are sold;

 

(b)              
prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in
connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition
of all securities covered by such registration statement;

 

(c)              
furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required
by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition
of their Registrable Securities;

 

    7

     

    

 

(d)              
use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under
such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided
that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such
states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by
the Securities Act;

 

(e)              
in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement,
in usual and customary form, with the underwriter(s) of such offering;

 

(f)               
use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement
to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which
similar securities issued by the Company are then listed;

 

(g)              
provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide
a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

 

(h)              
promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition
pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected
by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested
by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy
of the information in such registration statement and to conduct appropriate due diligence in connection therewith;

 

(i)                
notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement
has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 

(j)                
after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company
amend or supplement such registration statement or prospectus.

 

In addition, the Company
shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under
the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may
implement a trading program under Rule 10b5-1 of the Exchange Act.

 

2.5            
Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant
to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the
Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such
securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.

 

    8

     

    

 

2.6            
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings,
or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and
accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for
the selling Holders selected by the holders of a majority of the Registrable Securities sought to be included in such registration
(“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company
shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration
request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in
which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to
be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their
right to one registration pursuant to Section 2.1 or Section 2.1(b), as the case may be; provided further
that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business,
or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not
forfeit their right to one registration pursuant to Section 2.1 or Section 2.1(b). All Selling Expenses relating
to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the
basis of the number of Registrable Securities registered on their behalf.

 

2.7            
Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying
any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation
or implementation of this Section 2.

 

2.8            
Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:

 

(a)              
To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members,
officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter
(as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within
the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter,
controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with
investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such
claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions
made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration.

 

    9

     

    

 

(b)              
To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company,
and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls
the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined
in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any
such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based
upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling
Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any
claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement
contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such
settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further
that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Section 2.8(b)
and Section 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid
by such Holder), except in the case of fraud or willful misconduct by such Holder.

 

(c)              
Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will,
if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the
extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given,
and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to
retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests
between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any
liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying
party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Section 2.8.

 

    10

     

    

 

(d)              
To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either:
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8
but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration
of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding
the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act
may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and
in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they
may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of
the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted
in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative
fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether
the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge,
access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such
case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities
offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not
guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to
this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed
the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of
willful misconduct or fraud by such Holder.

 

(e)              
Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the
provisions in the underwriting agreement shall control.

 

(f)               
Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering,
the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable
Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

 

2.9            
Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other
rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration
or pursuant to a registration on Form S-3, the Company shall:

 

(a)              
make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144,
at all times after the effective date of the registration statement filed by the Company for the IPO;

 

    11

     

    

 

(b)              
 use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting
requirements); and

 

(c)              
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent
accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time
after 90 days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and
the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the
most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii)
such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits
the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements
under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).

 

2.10         
Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without
the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement
with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder to (i)
include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include
such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of
the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand
for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to
Registrable Securities acquired by any additional Investor who becomes a party to this Agreement in accordance with Section
6.9.

 

2.11         
“Market Standoff” Agreement. Each Holder hereby agrees that it will not, without the prior written consent
of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO, and ending
on the date specified by the Company or the managing underwriter (such period not to exceed 180 days), or such other period as
may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution
of research reports, and (2) analyst recommendations or opinions, including, but not limited to, the restrictions contained in
FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (a) lend; offer; pledge; sell;
contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or
warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of the Company’s capital stock
held immediately before the effective date of the registration statement for the IPO or (b) enter into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of the Company’s capital stock
whether any such transaction described in clause (a) or (b) above is to be settled by delivery of the Company’s capital
stock or other securities, in cash or otherwise. The foregoing provisions of this Section 2.11 shall not apply to the sale
of any shares to an underwriter pursuant to an underwriting agreement. The foregoing provisions of this Section 2.11 shall
not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the
Holders if all officers, directors and holders of more than 5% of the outstanding Common Stock (after giving effect to the conversion
into Common Stock of all outstanding Preferred Stock) enter into similar agreements. The underwriters in connection with the IPO
are intended third party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the
provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably
requested by the underwriters in the IPO that are consistent with this Section 2.11 or that are necessary to give further
effect thereto.

 

    12

     

    

 

2.12         
Restrictions on Transfer.

 

(a)              
The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company
shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or
transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred
Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and
upon the conditions specified in this Agreement.

 

(b)              
Each certificate, instrument or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii)
any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend,
recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c))
be notated with a legend substantially in the following form:

 

THE SECURITIES
REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF SAID ACT.

 

THE SECURITIES
REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN INVESTOR RIGHTS AGREEMENT BETWEEN THE COMPANY AND
THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

The Holders consent
to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in
order to implement the restrictions on transfer set forth in this Section 2.12.

 

    13

     

    

 

(c)              
The holder of such Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a
registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the
Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner
and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company,
shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal
opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction
may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect
that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation
by the staff of the SEC that action be taken with respect thereto or (iii) any other evidence reasonably satisfactory to counsel
to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without
registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or
transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company
will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144;
or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration;
provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate, instrument,
or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer
is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate,
instrument or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the
Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.

 

2.13         
Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities
in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to occur of:

 

(a)              
the closing of a Deemed Liquidation Event (as defined in the Certificate);

 

(b)              
such time after consummation of the IPO as Rule 144 or another similar exemption under the Securities Act is available
for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and

 

(c)              
the third anniversary of the IPO.

 

3.                 
Information and Observer Rights.

 

3.1             
Delivery of Financial Statements. The Company shall deliver to each Major Investor:

 

(a)              
by March 31, 2016, (i) an unaudited balance sheet for fiscal year 2015, (ii) unaudited statements of income and of cash
flows for fiscal year 2015 and (iii) an unaudited statement of stockholders’ equity for fiscal year 2015;

 

    14

     

    

 

 

(b)              
 beginning with fiscal year 2016, as soon as practicable, but in any event within 150 days after the end of each fiscal
year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year
and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified
by independent public accountants of regionally recognized standing selected by the Company;

 

(c)              
as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each fiscal
year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as
of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject
to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);

 

(d)              
such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as
any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated
under this Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret
or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company);
or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.

 

If, for any period, the
Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial
statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the
Company and all such consolidated subsidiaries.

 

Notwithstanding anything
else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section
3.1 during the period starting with the date 30 days before the Company’s good-faith estimate of the date of filing
of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration
statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated
at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement
to become effective.

 

3.2             
Inspection. The Company shall permit each Major Investor, at such Investor’s expense, to visit and inspect the
Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts
with its officers, during normal business hours of the Company as may be reasonably requested by such Investor; provided, however,
that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably
and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality
agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege
between the Company and its counsel.

 

    15

     

    

 

3.3             
Termination of Information Rights. The covenants set forth in Section 3.1 and Section 3.2 shall terminate
and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject
to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act or (iii) upon the closing of a Deemed Liquidation
Event (as defined in the Certificate), whichever event occurs first.

 

3.4             
Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or
use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company
pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement),
unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach
of this Section 3.4 by such Investor), (b) is or has been independently developed or conceived by such Investor without
use of the Company’s confidential information or (c) is or has been made known or disclosed to such Investor by a third
party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however,
that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals
to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective
purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions
of this Section 3.4; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor
in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and
directs such Person to maintain the confidentiality of such information or (iv) as may otherwise be required by law, regulation,
rule, court order or subpoena, provided that such Investor promptly notifies the Company of such disclosure and takes reasonable
steps to minimize the extent of any such required disclosure. Notwithstanding the foregoing, except in the case of clause (a)
above, in no event shall any Investor disclose or divulge any such confidential information to any firm or corporation, or any
employees, consultant or Affiliate of such firm or corporation, which competes with the Company.

 

4.            Rights
to Future Stock Issuances.

 

4.1             
Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws,
if the Company proposes to offer or sell any New Securities, the Company shall first offer the right to purchase such New Securities
(the “Offered New Securities”) to the Preemptive Rights Holders. The amount of Offered New Securities that
each Preemptive Rights Holder has the right to purchase is as set forth in Section 4.1(b). A Preemptive Rights Holder shall
be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among itself
and its Affiliates.

 

(a)              
The Company shall give notice (the “Offer Notice”) to each Preemptive Rights Holder, stating (i) its
bona fide intention to offer the Offered New Securities, (ii) the number of Offered New Securities to be offered and (iii) the
price and terms, if any, upon which it proposes to offer the Offered New Securities.

 

    16

     

    

 

(b)              
By notification to the Company within 10 days after the Offer Notice is given, each Preemptive Rights Holder may elect
to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of the Offered
New Securities which equals the proportion that the Common Stock issued or held, or issuable (directly or indirectly) upon conversion
and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Preemptive Rights
Holder bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable,
of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such 20 day period, the Company
shall promptly notify each Preemptive Rights Holder that elects to purchase or acquire all the shares available to it (each, a
 “Fully Exercising Investor”) of any other Preemptive Rights Holder’s failure to do likewise. During the
ten day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the
Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the Offered
New Securities for which Preemptive Rights Holders were entitled to subscribe but that were not subscribed for by the Preemptive
Rights Holders which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon
conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising
Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable,
of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such
unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of 90 days of
the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c).

 

(c)              
If all Offered New Securities are not elected to be purchased or acquired as provided in Section 4.1(b), the Company
may, during the 180 day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining
unsubscribed portion of the Offered New Securities to any Person or Persons at a price not less than, and upon terms no more favorable
to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the
unsubscribed portion of the Offered New Securities within such period, or if such agreement is not consummated within 30 days
of the execution thereof, the right provided hereunder shall be deemed to be revived and the unsubscribed portion of the Offered
New Securities shall not be offered unless first reoffered to the Preemptive Rights Holders in accordance with this Section
4.1.

 

(d)              
The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in the
Certificate) or (ii) shares of Common Stock issued in the IPO.

 

4.2             
Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i)
immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements
of Section 12(g) or 15(d) of the Exchange Act or (iii) upon the closing of a Deemed Liquidation Event (as defined in the Certificate),
whichever event occurs first.

 

5.            Additional
Covenants.

 

5.1             
Insurance. The Company shall maintain, from financially sound and reputable insurers directors and officers liability
insurance in an amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable
efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines that such insurance
should be discontinued. The policy shall not be cancelable by the Company without prior approval by the Board of Directors.

 

5.2             
Employee Agreements. The Company will cause each Person now or hereafter employed by the Company or by any subsidiary
(or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential and proprietary
information and/or trade secrets to enter into a nondisclosure and proprietary information and inventions assignment agreement,
substantially in the form approved by the Board of Directors, which shall include, where appropriate for such Person’s role
with the Company, acceptable noncompetition and nonsolicitation provisions. In addition, the Company shall not terminate or, in
any material respect amend, modify, waive any rights under or otherwise alter, in whole or in part, any of the above-referenced
agreements or any restricted stock agreement between the Company and any employee, without the prior approval of the Board of
Directors.

 

5.3             
Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company
who purchase, receive options to purchase or receive awards of shares of the Company’s capital stock after the date hereof
shall be required to execute restricted stock or option agreements, as applicable, providing for (a) vesting of shares over a
four year period, with the first 25% of such shares vesting following 12 months of continued employment or service, and the remaining
shares vesting in equal monthly installments over the following 36 months, and (b) a market standoff provision substantially similar
to that in Section 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain (and
not waive) a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right
to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock.

 

5.4             
Qualified Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Preferred
Stock, as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue
Code (the “Code”), to constitute “qualified small business stock” as defined in Section 1202(c)
of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors determines, in
its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company. The Company
shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that are required under
Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder.

 

5.5             
Matters Requiring Board Approval. So long as the holders of Preferred Stock are entitled to elect a Series A Director,
the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors:

 

(a)              
make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary
or other corporation, partnership or other entity unless it is wholly owned by the Company;

 

(b)              
make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee
or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under
the terms of an equity incentive plan or other compensatory arrangement approved by the Board of Directors;

 

    17

     

    

 

(c)              
guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except
for trade accounts of the Company or any subsidiary arising in the ordinary course of business;

 

(d)              
make any investment inconsistent with any investment policy approved by the Board of Directors;

 

(e)              
incur any aggregate indebtedness in excess of $100,000 that is not already included in a budget approved by the Board of
Directors, other than trade credit incurred in the ordinary course of business;

 

(f)               
otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any “associate”
(as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including without limitation any “management
bonus” or similar plan providing payments to employees in connection with a Deemed Liquidation Event (as defined in the
Certificate), except for transactions contemplated by the Transaction Agreements (as defined in the 2020 Purchase Agreement);
transactions resulting in payments to or by the Company in an aggregate amount less than $100,000 per year; or transactions made
in the ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable
terms that are approved by the Board of Directors;

 

(g)              
hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards
to executive officers;

 

(h)              
change the principal business of the Company, enter new lines of business, or exit the current line of business;

 

(i)                
sell, assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in
the ordinary course of business; or

 

(j)                
enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to
the Company of money or assets greater than $100,000.

 

5.6             
Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of
Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors
for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with
attending meetings of the Board of Directors.

 

5.7             
Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any
other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent
necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company
with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether
such obligations are contained in the Company’s Bylaws, its Certificate or elsewhere, as the case may be.

 

    18

     

    

 

5.8             
Indemnification Matters. The Company hereby acknowledges that one or more of the directors nominated to serve on the
Board of Directors by the Investors (each an “Investor Director”) may have certain rights to indemnification,
advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively,
the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e.,
its obligations to any such Investor Director are primary and any obligation of the Investor Indemnitors to advance expenses or
to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it
shall be required to advance the full amount of expenses incurred by such Investor Director and shall be liable for the full amount
of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the
extent legally permitted and as required by the Certificate or Bylaws of the Company (or any agreement between the Company and
such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors, and (c)
that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors
for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement
or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor
Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right
of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor
Director against the Company. The Investor Directors and the Investor Indemnitors are intended third-party beneficiaries of this
Section 5.8 and shall have the right, power and authority to enforce the provisions of this Section 5.8 as though
they were a party to this Agreement.

 

5.9             
Termination of Covenants. The covenants set forth in this Section 5, except for Section 5.5, shall terminate
and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject
to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act or (iii) upon a Deemed Liquidation Event
(as defined in the Certificate), whichever event occurs first.

 

5.10         
Harassment Policy. The Company shall adopt and thereafter maintain in effect (i) a Code of Conduct governing appropriate
workplace behavior and (ii) an Anti-Harassment and Discrimination Policy prohibiting discrimination and harassment at the Company.
Such policy shall be reviewed and approved by the Board of Directors.

 

    19

     

    

 

6.             Miscellaneous.

 

6.1             
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by
a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family
Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; (iii)
after such transfer, holds at least 65,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits,
stock dividends, combinations, and other recapitalizations) or (iv) any other transferee that is not a competitor of the Company,
as reasonably determined by the Board of Directors; provided, however, that (x) the Company is, within a reasonable time
after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with
respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company
to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For
the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee
(1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust
for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those
of the transferring Holder; provided, further, that all transferees who would not qualify individually for assignment of
rights shall, as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any
rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the
benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express
or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees
any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.

 

6.2             
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware,
regardless of the laws that might otherwise govern under applicable principles of conflicts of law.

 

6.3             
Counterparts. This Agreement may be executed and delivered by facsimile signature and in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail by scanned pdf counterparts of signature pages, or other such electronic means
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

6.4             
Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

6.5             
Notices.

 

(a)              
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or (a) personal delivery to the party to be notified; (b) when sent, if sent by electronic
mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the
recipient’s next business day; (c) five days after having been sent by registered or certified mail, return receipt requested,
postage prepaid; or (d) one business day after the business day of deposit with a nationally recognized overnight courier, freight
prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective
parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention
of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently
modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, it shall be sent
to 665 Stockton Drive #300, Exton, PA 19341, Attn: Chief Executive Officer (electronic mail: psarma@immunome.com); and, in the
case of notice given to the Company, a copy (which shall not constitute notice) shall also be sent to Duane Morris LLP, 30 S.
17th St, Philadelphia, PA 19103, Attn: Sandra G. Stoneman (facsimile: (215) 689-4420; electronic mail: sgstoneman@duanemorris.com).

 

    20

     

    

 

(b)              
Consent to Electronic Notice. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware
General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission
pursuant to Section 232 of the DGCL (or any successor thereto) at such Investor’s electronic mail address or the facsimile
number set forth on Schedule A hereto, or as subsequently modified by written notice given in accordance with this Section
6.5. Each Investor agrees to promptly notify the Company of any change in its electronic mail address, and that failure to
do so shall not affect the foregoing.

 

6.6             
Amendments and Waivers. This Agreement may be amended, modified or terminated and the observance of any term hereof
may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument
executed by (x) the Company and (y) the Holders of at least a majority of the Registrable Securities. Notwithstanding the foregoing:

 

(a)              
the Company may in its sole discretion waive compliance with Section 2.12(c);

 

(b)              
this Agreement may not be amended, modified or terminated and the observance of any term of this Agreement may not be waived
with respect to any Investor without the written consent of such Investor unless such amendment, modification, termination or
waiver applies to all Investors in the same fashion;

 

(c)              
Schedule A hereto may be amended by the Company from time to time to add information regarding Investors without
the consent of the other parties hereto; and

 

(d)              
any provision hereof may be waived by the waiving party on such party’s own behalf, without the consent of any other
party.

 

Any amendment, modification,
termination or waiver effected in accordance with this Section 6.6 shall be binding on each party and all of such party’s
successors and permitted assigns, whether or not any such party, successor or assignee entered into or approved such amendment,
modification, termination or waiver. For purposes of this Section 6.6, the requirement of a written instrument may be satisfied
in the form of an action by written consent of the stockholders circulated by the Company and executed by the stockholder parties
specified, whether or not such action by written consent makes explicit reference to the terms of this Agreement. No waivers of
or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed
as, a further or continuing waiver of any such term, condition or provision.

 

    21

     

    

 

6.7             
 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision
of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law.

 

6.8             
Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together
for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such
rights as among themselves in any manner they deem appropriate.

 

6.9             
Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares
of Preferred Stock after the date hereof, whether pursuant to the 2020 Purchase Agreement or otherwise, as a condition to the
issuance of such shares, the Company shall require that any purchaser of such shares of Preferred Stock become a party to this
Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed
an Investor for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement
by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as
an Investor hereunder.

 

6.10         
Entire Agreement. This Agreement (including the Schedules hereto), the Certificate and the other Transaction Agreements
(as defined in the 2020 Purchase Agreement) constitutes the full and entire understanding and agreement among the parties with
respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between
the parties is expressly canceled. Without limitation of the foregoing, this Agreement amends and restates, and supersedes in
its entirety, the Original Agreement.

 

6.11         
Waiver of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON
OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE
SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE
TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE),
BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION 6.11 HAS BEEN FULLY DISCUSSED BY EACH OF THE
PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS
THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY
TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

    22

     

    

 

6.12         
Arbitration. Any controversy or claim arising out of or relating to this Agreement that remains unresolved for more
than 30 days after the matter is first raised by a party to the other party or parties, except as (i) otherwise provided in this
Agreement, or (ii) any such controversies or claims arising out of either party’s intellectual property rights for which
a provisional remedy or equitable relief is sought, shall be submitted to arbitration by one arbitrator from names of potential
arbitrators proposed by the American Arbitration Association (the “AAA”) mutually agreed upon by the applicable
parties, and if no agreement can be reached within 30 days after names have been proposed by the AAA, then by one arbitrator having
reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the AAA.
The arbitration shall take place in New Castle County, Delaware, in accordance with the AAA rules then in effect, and judgment
upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There
shall be limited discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary
evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses and (c)
such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance
with the Delaware Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis for
the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official
transcript of such proceedings.

 

6.13         
Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this
Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of
such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default,
or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise
afforded to any party, shall be cumulative and not alternative.

 

6.14         
Schedules. The Stockholders acknowledge and understand that the Schedules to this Agreement have been intentionally
omitted. Information on the Schedules will be provided upon the request of any Stockholder, subject to redaction of information
regarding any other Stockholder.

 

(Signature page follows.)

 

    23

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	IMMUNOME,
    INC.
	 	 
	 	By: 	/s/
    Purnanand Sarma
	 	 	Purnanand
    Sarma
	 	 	Chief
    Executive Officer and President

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Sharad Adekar
	 	Signature
	 	 
	 	Sharad
    Adekar
	 	Name
	 	 
	 	/s/
    Sangeeta Raina
	 	Signature
    (if more than one)*
	 	 
	 	Sangeeta
    Raina
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Adhesive
    Innovations 401K Plan Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 
    	/s/
    David W. Freelove
	 	 	Signature
	 	 
	 	David
    W. Freelove - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Steven J. Albert
	 	Signature
	 	 
	 	Steven
    J. Albert
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	The
    Arkit Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Bellevue Enterprise Management (PTC) S.A.
	 	 	Signature
	 	 
	 	Bellevue
    Enterprise Management (PTC) S.A.
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Asphalt
    and Roadway Workers 401K Plan Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 
    	/s/
    David W. Freelove
	 	 	Signature
	 	 
	 	David
    W. Freelove - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Sonia Attkiss
	 	Signature
	 	 
	 	Sonia
    Attkiss
	 	Name
	 	 
	 	/s/
    Keith Attkiss
	 	Signature
    (if more than one)*
	 	 
	 	Keith
    Attkiss
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    	 

    	 

    

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Jonathan Auerbach
	 	Signature
	 	 
	 	Jonathan
    Auerbach
	 	Name
	 	 
	 	/s/
    Karoline Adler
	 	Signature
    (if more than one)*
	 	 
	 	Karoline
    Adler
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Automotive
    Assemblers 401K Plan Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 
    	/s/
    David W. Freelove
	 	 	Signature
	 	 
	 	David
    W. Freelove - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Michael Balducci
	 	Signature
	 	 
	 	Michael
    Balducci
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Neehar Banerji
	 	Signature
	 	 
	 	Neehar
    Banerji
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    24

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Louis J. Basenese III
	 	Signature
	 	 
	 	Louis
    J. Basenese III
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    25

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    David Bruce Benson
	 	Signature
	 	 
	 	David
    Bruce Benson
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    26

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    John Bindseil
	 	Signature
	 	 
	 	John
    Bindseil
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    27

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Richard Bindseil
	 	Signature
	 	 
	 	Richard
    Bindseil
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    28

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	BioAdvance
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Gregory Harriman
	 	 	Signature
	 	 
	 	Gregory
    Harriman – Vice President
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    29

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Scott Chait
	 	Signature
	 	 
	 	Scott
    Chait
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    30

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	The
    Chambers Family Living Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Charles Chambers
	 	 	Signature
	 	 
	 	Charles
    Chambers - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    31

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Emily Cohen
	 	Signature
	 	 
	 	Emily
    Cohen
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    32

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Joseph M. Cohen
	 	Signature
	 	 
	 	Joseph
    M. Cohen
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    33

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 

	 	/s/
    Neil M. Cohen
	 	Signature
	 	 
	 	Neil M.
    Cohen
	 	Name
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	Name (if
    more than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:

 

	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	     Signature
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 
	 	 

*If joint stockholders,
both must sign.

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	Signature
	 	 
	 	Name
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	Name (if more
    than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:

 

	 	Cotswold
    Foundation
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    I. Wistar Morris
	 	 	      Signature
	 	 
	 	I.
    Wistar Morris
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 
	 	 

*If joint stockholders,
both must sign.

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	Signature
	 	 
	 	Name
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	Name (if more
    than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:

 

	 	Daybreak
    Associates LLC
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    Maurice Haroche
	 	 	      Signature
	 	 
	 	Maurice
    Haroche
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 
	 	 

*If joint stockholders,
both must sign.

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	Signature
	 	 
	 	Name
	 	 
	 	Signature (if more than one)*
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 

 

	 	Design
    Alliance 401K Plan Trust
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    David W. Freelove
	 	 	      Signature
	 	 
	 	David
    W. Freelove - Trustee
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 
	 	 

*If joint stockholders,
both must sign. 

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	Signature
	 	 
	 	Name
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	Name (if more
    than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:

 

	 	DeSimone
    Group Investments, LLC
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    Michael DeSimone
	 	 	         Signature
	 	 
	 	Michael
    DeSimone - CEO
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign. 

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	Signature
	 	 
	 	Name
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	Name (if more
    than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:

 

	 	DSDS
    Partners LLC
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    Daniel Saks
	 	 	   Signature
	 	 
	 	Daniel
    Saks, Manager
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/
    Louis C. Dwyer
	 	Signature
	 	 
	 	Louis C.
    Dwyer
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name (if more
    than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:

 

	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	      Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign. 

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	Signature
	 	 
	 	Name
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	Name (if more
    than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 

	 	Eisenberg
    Family Partnership, LTD
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    Mitchell Eisenberg
	 	 	     Signature
	 	 
	 	Mitchell
    Eisenberg, Manager
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 
	 	 

*If joint stockholders,
both must sign. 

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	Signature
	 	 
	 	Name
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	Name (if more
    than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:

 

	 	Elliot-Herbst
    Family LLC
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    Alice Elliot-Herbst
	 	 	      Signature
	 	 
	 	Alice
    Elliot-Herbst – Managing Member
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	Signature
	 	 
	 	Name
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	Name (if more
    than one)*
	 	 
	 	Corporations, Trusts, Partnerships,
    Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:

 

	 	John
    A. Elway Revocable Trust
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    John A. Elway
	 	 	       Signature
	 	 
	 	John
    A. Elway - Trustee
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to
Immunome, Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts,
    Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	EMDD
	 	Name of Stockholder (please
    print)
	 	 
	 	By:	/s/
    D. Duffy
	 	 	Signature
	 	 
	 	D.
    Duffy – Managing Member
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Philip Eytan
	 	Signature
	 	 
	 	Philip Eytan
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	            
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Fiberboard Production 401K
    Plan Trust
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ David W.Freelove
	 	 	Signature
	 	 
	 	David W. Freelove - Trustee
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Christopher J.
    Fiore
	 	Signature
	 	 
	 	Christopher J. Fiore
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Four Kids Investment Fund
    LLC
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Jonathan Honig
	 	 	Signature
	 	 
	 	Jonathan Honig, Manager
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Four Tree Trust dated June
    3, 2019
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Mark L. Baum    /s/
    Mark L. Baum
	 	 	Signature
	 	 
	 	Mark L. Baum and Emily C.
    Baum as Co-Trustees
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ David W. Freelove
	 	Signature
	 	 
	 	David W. Freelove
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Giant Foods 401K Plan Trust
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ David W. Freelove
	 	 	Signature
	 	 
	 	David W. Freelove - Trustee
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Renat Gibadullin
	 	Signature
	 	 
	 	Renat Gibadullin
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Gregory
    A. and Michele Goodwin Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Gregory A. Goodwin
	 	 	Signature
	 	 
	 	Gregory
    A. Goodwin - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	GS
    Venture Partners LLC
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Gregg Smith
	 	Signature
	 	 
	 	Gregg
    Smith – Managing Member
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	G-Ten
    Partners LLC
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Jaime Hartman
	 	Signature
	 	 
	 	Jaime
    Hartman – Managing Member
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Timothy Hanley
	 	Signature
	 	 
	 	Timothy
    Hanley
	 	Name
	 	 
	 	/d/
    Monica Hanley
	 	Signature
    (if more than one)*
	 	 
	 	Monica
    Hanley
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                                  
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Matthew Hayden
	 	Signature
	 	 
	 	Matthew
    Hayden
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                             
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Lawrence
    J. Hollander Revocable Living Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Lawrence J. Hollander
	 	Signature
	 	 
	 	Lawrence
    J. Hollander - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	HUG
    Funding LLC
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Jaime Hartman
	 	Signature
	 	 
	 	Jaime
    Hartman – Managing Member
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Huneke
    Family Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Murray Huneke
	 	Signature
	 	 
	 	Murray
    Huneke - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Dev B. Kapadia
	 	Signature
	 	 
	 	Dev
    B. Kapadia
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	            
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Scott Klansky
	 	Signature
	 	 
	 	Scott
    Klansky
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                  
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Kenneth Koch
	 	Signature
	 	 
	 	Kenneth
    Koch
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                   
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Antonia Kolokathis,
    MD
	 	Signature
	 	 
	 	Antonia Kolokathis, MD
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature
Page to Immunome, Inc. Amended and Restated Investor Rights Agreement) 

 

    1

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Matthew M. Kremer
	 	Signature
	 	 
	 	Matthew
    M. Kremer
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    2

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Kremer/Miller
    Family Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    David H. Kremer
	 	 	Signature
	 	 
	 	David
    H. Kremer - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    3

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Kenneth Kutcher
	 	Signature
	 	 
	 	Kenneth
    Kutcher
	 	Name
	 	 
	 	/s/
    Barbara Kutcher
	 	Signature
    (if more than one)*
	 	 
	 	Barbara
    Kutcher
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    4

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	John
    L. LaMattina Revocable Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    John L. LaMattina
	 	 	Signature
	 	 
	 	John
    L. LaMattina, Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    5

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    David D. Langfitt
	 	Signature
	 	 
	 	David
    D. Langfitt
	 	Name
	 	 
	 	/s/
    Margaret B. Langfitt
	 	Signature
    (if more than one)*
	 	 
	 	Margaret
    B. Langfitt
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    6

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Lankenau
    Institute for Medical Research
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    George Prendergast
	 	 	Signature
	 	 
	 	George
    Prendergast, MD - President and CEO
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    David Jason Lapadula
	 	Signature
	 	 
	 	David
    Jason Lapadula
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    7

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 /s/
    Elizabeth S. Lapadula
	 	Signature
	 	 
	 	Elizabeth
    S. Lapadula
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature
Page to Immunome, Inc. Amended and Restated Investor Rights Agreement) 

 

    8

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Jonathan Lawrie
	 	Signature
	 	 
	 	Jonathan
    Lawrie
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    9

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Michael Lefenfeld
	 	Signature
	 	 
	 	Michael Lefenfeld
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	        Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Roland J. Lewis
    III
	 	Signature
	 	 
	 	Roland J. Lewis III
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	      Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Steven L. Ludmerer Revocable Living Trust
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Steven Ludmerer
	 	 	      Signature
	 	 
	 	Steven Ludmerer - Trustee
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Mainstar Trust FBO
    Leonard Barshack Roth IRA #R217497
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Leonard Barshack
	 	 	    Signature
	 	 
	 	Leonard Barshack
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Bruce E. Maryanoff
	 	Signature
	 	 
	 	Bruce E. Maryanoff
	 	Name
	 	 
	 	/s/ Cynthia A. Maryanoff
	 	Signature (if more than one)*
	 	 
	 	Cynthia A. Maryanoff
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	     Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ John Masouras
	 	Signature
	 	 
	 	John Masouras
	 	Name
	 	 
	 	/s/ Joann Masouras
	 	Signature (if more than one)*
	 	 
	 	Joann Masouras
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	     Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Mid-Atlantic Angel
    Group II
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Jeffrey Snellenburg
	 	 	     Signature
	 	 
	 	Jeffrey Snellenburg
    – Executive Director
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	MJ Doubletrees LLC
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Sharon Shtern
	 	 	    Signature
	 	 
	 	Sharon Shtern - Manager
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Monoclonal Antibodies LLC
	 	Name of Stockholder (please print)
	 	 
	 	By: 	/s/ David W. Freelove
	 	 	    Signature
	 	 
	 	David W. Freelove –
    Managing Member
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ William D. Moreland
	 	Signature
	 	 
	 	William D. Moreland
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	      Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    I. Wistar Morris
	 	Signature
	 	 
	 	I.
    Wistar Morris
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Joseph Muoio
	 	Signature
	 	 
	 	Joseph
    Muoio
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Stephen J. Negrotti
	 	Signature
	 	 
	 	Stephen
    J. Negrotti
	 	Name
	 	 
	 	/s/
    Joyce A. Negrotti
	 	Signature
    (if more than one)*
	 	 
	 	Joyce
    A. Negrotti
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Northwest
    Wood Products 401K Plan Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 
    	/s/
    David W. Freelove
	 	 	Signature
	 	 
	 	David
    W. Freelove - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Painting
    and Paper Hangers 401K Plan Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 
    	/s/
    David W. Freelove
	 	 	Signature
	 	 
	 	David
    W. Freelove - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Joseph Papa
	 	Signature
	 	 
	 	Joseph
    Papa
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Pensco
    Trust Co Custodian FBO Grant Devaul IRA
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	/s/
    Grant Devaul
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Stephen L. Phillips
	 	Signature
	 	 
	 	Stephen
    L. Phillips
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Pierce
    Family Trust dated 9/13/00
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	/s/
    Mitchell D. Pierce /s/ Julie Pierce
	 	 	Signature
	 	 
	 	Mitchell
    D. Pierce – Trustee
 Julie Pierce - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Richard Pigossi
	 	Signature
	 	 
	 	Richard
    Pigossi
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By: 	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	PKBT HoldingsLLC
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Mark Hossein
	 	 	Signature
	 	 
	 	Mark Hossein - CFO
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Plumbers Union 401K Plan
    Trust
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ David W. Freelove
	 	 	Signature
	 	 
	 	David W. Freelove - Trustee
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Jason Port
	 	Signature
	 	 
	 	Jason Port
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Simon Posen
	 	Signature
	 	 
	 	Simon Posen
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Printech LLC
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Joseph Muoio
	 	 	Signature
	 	 
	 	Joseph Muoio - President
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Eric Raphael
	 	Signature
	 	 
	 	Eric Raphael
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign. 

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Michael Rapoport
	 	Signature
	 	 
	 	Michael Rapoport
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Retail Merchants 401K Plan
    Trust
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ David W. Freelove
	 	 	Signature
	 	 
	 	David W. Freelove - Trustee
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	/s/ Leslie D. Reyes
	 	Signature
	 	 
	 	Leslie D. Reyes
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature (if more than one)*
	 	 
	 	 
	 	Name (if more than one)*
	 	 
	 	Corporations, Trusts, Partnerships, Limited Liability
    Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Robin Hood Ventures
	 	Name of Stockholder (please print)
	 	 
	 	By:	/s/ Ellen Weber
	 	 	Signature
	 	 
	 	Ellen Weber
	 	(print name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    

     

    

 

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Robin
    Hood Ventures 5 4 LP
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Ellen Weber
	 	 	Signature
	 	 
	 	Ellen
    Weber – Corresponding Secretary
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    1

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Rono
    LLC
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Rohen Oza
	 	 	Signature
	 	 
	 	Rohen
    Oza, Manager
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    2

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    David Rosenberg
	 	Signature
	 	 
	 	David
    Rosenberg
	 	Name
	 	 
	 	/s/
    David Rosenberg
	 	Signature
    (if more than one)*
	 	 
	 	Dara
    Rosenberg
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    3

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	The
    Rothstein Family Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Robert Rothstein
	 	 	Signature
	 	 
	 	Robert
    Rothstein - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    4

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Thomas M. Ryan
	 	Signature
	 	 
	 	Thomas
    M. Ryan
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature
Page to Immunome, Inc. Amended and Restated Investor Rights Agreement) 

 

    5

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Harvey Schiller
	 	Signature
	 	 
	 	Harvey
    Schiller
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    6

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Anthony Sciscione
	 	Signature
	 	 
	 	Anthony
    Sciscione
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    7

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Elizabeth D. Sigety
	 	Signature
	 	 
	 	Elizabeth
    D. Sigety
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    8

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Jeffrey Snellenburg
	 	Signature
	 	 
	 	Jeffrey
    Snellenburg
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    9

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Southern
    NE Cable 401K Plan Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    David W. Freelove
	 	 	Signature
	 	 
	 	David
    W. Freelove – Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    10

     

    

 

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Jeffrey
    Sperbeck 2012 Revocable Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Jeffrey M. Sperbeck
	 	 	Signature
	 	 
	 	Jeffrey
    M. Sperbeck - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    11

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Jeffrey A. Springer
	 	Signature
	 	 
	 	Jeffrey
    A. Springer
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature
Page to Immunome, Inc. Amended and Restated Investor Rights Agreement) 

 

    12

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    David Stern
	 	Signature
	 	 
	 	David
    Stern
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    13

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	The
    David S Stern 2014 Family Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    David Stern
	 	 	Signature
	 	 
	 	David
    Stern
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    14

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Sandra Stoneman
	 	Signature
	 	 
	 	Sandra
    Stoneman
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    15

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	The
    Sugar Investment Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Alex Sugar
	 	 	Signature
	 	 
	 	Alex
    Sugar
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    16

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Sunco
    Property Investment LLC
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Joseph Cohen
	 	 	Signature
	 	 
	 	Joseph
    Cohen - Manager
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    17

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	The
    Tandemit Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Bellevue Enterprise Management (PTC) S.A.
	 	 	Signature
	 	 
	 	Bellevue
    Enterprise Management (PTC) S.A.
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    18

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    William D. Toler
	 	Signature
	 	 
	 	William
    D. Toler
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement) 

 

    19

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Adam Turteltaub
	 	Signature
	 	 
	 	Adam
    Turteltaub
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	 
	 	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If
joint stockholders, both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

    20

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Judith Tytel
	 	Signature
	 	 
	 	Judith
    Tytel
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                    
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	US
    Surface Engineers 401K Plan Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    David W. Freelove
	 	Signature
	 	 
	 	David
    W. Freelove - Trustee
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Antoine Verglas
	 	Signature
	 	 
	 	Antoine
    Verglas
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	              
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	VOJ
    LLC
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	/s/
    Michael Thompson
	 	Signature
	 	 
	 	Michael
    Thompson
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Jacob Widlitz
	 	Signature
	 	 
	 	Jacob
    Widlitz
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Michael D. Widlitz
	 	Signature
	 	 
	 	Michael
    D. Widlitz
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	The
    Woodland Trust
	 	Name
    of Stockholder (please print)
	 	 
	 	By:
    	/s/
    Michael A. Barth /s/ Bruno Schwendinger
	 	Signature
	 	 
	 	Michael
    A. BARTH & Bruno SCHWENDINGER
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
    Donald Zoltan
	 	Signature
	 	 
	 	Donald
    Zoltan
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Amended and Restated Investor Rights Agreement as of the date first written above.

 

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
                                         Ross Haley

	 	Signature
	 	 
	 	Ross
                                         Haley

	 	Name
	 	 
	 	/s/
    Kristina Haley
	 	Signature
    (if more than one)*
	 	 
	 	Kristina
                                         Haley

	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome, Inc. Amended
and Restated Investor Rights Agreement)

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	
/s/
                                         Michael J. Lapadula

	 	Signature
	 	 
	 	
Michael
                                         J. Lapadula

	 	Name
	 	 
	 	
	 	Signature
    (if more than one)*
	 	 
	 	

	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	/s/
                                         David Shorr

	 	Signature
	 	 
	 	David
                                         Shorr

	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name
    (if more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	 
	 	Name
    of Stockholder (please print)
	 	 
	 	By:	                
	 	Signature
	 	 
	 	 
	 	(print
    name and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 

 

*If joint stockholders, both must sign.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Amended and Restated Investor Rights Agreement as of the date first written above.

 

	 	Individuals
    Sign Below:
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name
	 	 
	 	 
	 	Signature
    (if more than one)*
	 	 
	 	 
	 	Name (if
    more than one)*
	 	 
	 	Corporations,
    Trusts, Partnerships, Limited Liability Companies, Retirement Plans, Retirement Accounts or Other Entities Sign Below:
	 	 
	 	Selma
    R. Williams 2010 Revocable Trust for 

    Wendy Koch Exempt Trust
	 	Name of Stockholder
    (please print)
	 	 
	 	By:	/s/
    Joel Papernik
	 	 	Signature
	 	 
	 	Joel
    Papernik, Trustee
	 	(print name
    and title of signatory)
	 	 
	 	Address:
	 	 
	 	 
	 	 
	 	 

 

*If joint stockholders,
both must sign.

 

(Signature Page to Immunome,
Inc. Amended and Restated Investor Rights Agreement)

 

     

     

    

 

Schedule A

List of Investors

 

	Investor
    
	Adam
    Turteltaub
	Adhesive
    Innovations 401K Plan Trust
	Aldy
    Corporation
	Allon
    Bloch
	Amitaf
    Alliances
	Anthony
    Sciscione
	Antoine
    Verglas
	Antonia
    Kolokathis, MD
	The
    Arkit Trust
	Asphalt
    and Roadway Workers 401K Plan Trust
	Automotive
    Assemblers 401K Plan Trust
	Ben
    Goldberg
	BioAdvance
	Bruce
    E. and Cynthia A. Maryanoff
	The
    Chambers Family Living Trust
	Christopher
    J. Fiore
	Connie
    S. P. Chen
	Cotswold
    Foundation
	Daniel
    Jason Lapadula
	David
    and Dara Rosenberg
	David
    Bruce Benson
	David
    D. and Margaret B. Langfitt
	David
    A. Shorr
	David
    Stern
	The
    David S. Stern 2014 Family Trust
	David
    W. Freelove
	Daybreak
    Associates LLC
	Deborah
    J. Ziskin

 

     

     

    

 

	Investor
	Design
    Alliance 401K Plan Trust
	DeSimone
    Group Investments, LLC
	Dev
    B. Kapadia
	Donald
    Zoltan
	Dr.
    Herbert S. Kronstadt Trust
	DSDS
    Partners LLC
	Eisenberg
    Family Partnership, LTD.
	Elizabeth
    D. Sigety
	Elizabeth
    S. Lapadula
	Elliot-Herbst
    Family LLC
	EMDD
	Emily
    Cohen
	Eric
    Raphael
	Fiberboard
    Production 401K Plan Trust
	Four
    Kids Investment Fund LLC
	Four
    Tree Trust dated June 3, 2019
	Genesis
    Asset Opportunity Fund LP
	Giant
    Foods 401K Plan Trust
	Gregory
    A and Michele Goodwin Trust
	GS
    Venture Partners LLC
	G-Ten
    Partners LLC
	Harvey
    Schiller
	Hermann
    M. Hessenbruch 1941 FBO Peter H. Havens
	Howard
    Steinberg and Karen Scappaticci
	HUG
    Funding LLC
	Huneke
    Family Trust
	HVA
    Limited Partnership
	I.
    Wistar Morris
	Jacob
    Widlitz
	JAMS
    Holdings LLC

 

     

     

    

 

	Investor
	Jason
    Port
	Jay
    Rappaport
	Jeffrey
    Snellenburg
	Jeffrey
    Sperbeck 2012  Revocable Trust
	Jeffrey
    A. Springer
	John
    A Elway Revocable Trust
	John
    and Joann Masouras
	John
    Bindseil
	John
    L. LaMattina Revocable Trust
	Jonathan
    Auerbach and Karoline Adler JTWROS
	Jonathan
    Lawrie
	Joseph
    M. Cohen
	Joseph
    Muoio
	Joseph
    Papa
	Joshua
    Bell
	Judith
    Tytel
	Kenneth
    and Barbara Kutcher
	Kenneth
    Koch
	Kremer/Miller
    Family Trust
	Lankenau
    Institute for Medical Research
	Lawrence
    J. Hollander Revocable Living Trust
	Leslie
    D. Reyes
	Louis
    C Dwyer
	Louis
    J. Basenese III
	Louis
    P. Wagman
	Louise
    A. Havens Trust
	Mainstar
    Trust FBO Leonard Barshack Roth IRA #R2177497
	Matthew
    Hayden
	Matthew
    M. Kremer

 

     

     

    

 

	Investor
	Michael
    Attkiss Family Trust
	Michael
    Balducci
	Michael
    D. Widlitz
	Michael
    J. Lapadula
	Michael
    Lefenfeld
	Michael
    Rapoport
	Mid-Atlantic
    Angel Group II
	MJ
    Doubletrees LLC
	MLS
    Trust FBO Robert H. Havens
	MLS
    Trust FBO Victoria L. Havens
	Monoclonal
    Antibodies LLC
	Neehar
    Banerji
	Neil
    M. Cohen
	Northwest
    Wood Products 401K Plan Trust
	Painting
    and Paper Hangers 401K Plan Trust
	Peachtree
    Investments, LLC
	Pensco
    Trust Co Custodian FBO Grant Devaul IRA
	Philip
    Eytan
	Pierce
    Family Trust Dated 9/13/00
	PKBT
    Holdings LLC
	Plumbers
    Union 401K Plan Trust
	Printech
    LLC
	Renat
    Gibadullin
	Retail
    Merchants 401K Plan Trust
	Richard
    Bindseil
	Richard
    Pigossi
	Robin
    Hood Ventures
	Robin
    Hood Ventures 54, LP
	Roland
    J. Lewis III

 

     

     

    

 

	Investor
	Rono
    LLC
	Ross
    Haley
	The
    Rothstein Family Trust
	Sandra
    Stoneman
	Schein
    Ventures, LLC
	Scott
    Chait
	Scott
    Klansky
	Selma
    R. Williams 2010 Revocable Trust for Wendy Koch Exempt Trust
	Sharad
    Adekar & Sangeeta Raina
	Shawn
    Langer
	Simon
    Posen
	Sonia
    & Keith Attkiss
	Southern
    NE Cable 401K Plan Trust
	Stephen
    J. Negrotti and Joyce A. Negrotti
	Stephen
    L. Phillips
	Steven
    J. Albert
	Steven
    L. Ludmerer Revocable Living Trust
	The
    Sugar Investment Trust
	Sunco
    Property Investment LLC
	The
    Tandemit Trust
	Theresa
    Natalicchio
	Thomas
    M. Ryan
	Timothy
    and Monica Hanley
	US
    Surface Engineers 401K Plan Trust
	VOJ
    LLC
	WarDen
    LLC
	William
    D. Toler
	William
    D. Moreland
	The
    Woodland TrustExhibit 4.3

 

NEITHER THIS WARRANT NOR THE SHARES PURCHASABLE UPON THE
EXERCISE HEREOF HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR THE SECURITIES LAWS OF ANY JURISDICTION. THESE SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION
OR AN EXEMPTION THEREFROM. BY ACQUIRING THIS WARRANT, THE HOLDER REPRESENTS THAT THE HOLDER WILL NOT SELL OR OTHERWISE DISPOSE
OF THIS WARRANT OR THE SHARES PURCHASABLE UPON EXERCISE HEREOF WITHOUT REGISTRATION OR OTHER COMPLIANCE WITH THE AFORESAID LAWS
AND THE RULES AND REGULATIONS THEREUNDER.

 

IMMUNOME, INC.

 

2020 SERIES A PREFERRED STOCK PURCHASE
WARRANT

 

	Warrant No. A-[___]	 	[•], 2020

 

THIS CERTIFIES that,
for value received, [Name] (“Holder”), or registered assigns, is entitled to subscribe for and purchase
from Immunome, Inc., a Delaware corporation (the “Company”), [___] shares of Series A
Preferred Stock of the Company, par value $0.0001 per share (the “Preferred Stock”), subject to adjustment from
time to time in accordance with Section 4 hereof, at a per-share purchase price equal to $1.50 (the “Warrant
Price”). This 2020 Series A Preferred Stock Purchase Warrant (this “Warrant”) is one of a series of
substantially identical warrants (collectively, the “Warrants”) issued by the Company in connection with the
transactions contemplated by that certain 2020 Series A Preferred Stock Purchase Agreement dated as of June 2, 2020
( the “Stock Purchase Agreement”).

 

Section 1.          Exercise and Duration of Warrant.

 

(a)       Exercise Procedures. Holder
may exercise this Warrant, in whole or in part, by presentation and surrender of this Warrant to the Company with the Form of
Subscription attached hereto duly executed and accompanied by payment of the full Warrant Price for each share to be purchased.

 

(b)       Issuance of Preferred
Stock. Upon receipt of this Warrant with the Form of Subscription duly executed and accompanied by payment of the
aggregate Warrant Price for the shares for which this Warrant is then being exercised, the Company shall cause to be issued
certificates for the total number of whole shares of Preferred Stock for which this Warrant is being exercised (adjusted to
reflect the effect of the provisions contained in Section 4 hereof, if any) in such denominations as are requested for
delivery to Holder, and the Company shall thereupon deliver such certificates to Holder. Holder shall be deemed to be the
holder of record of the shares of Preferred Stock issuable upon such exercise, notwithstanding that certificates representing
such shares of Preferred Stock shall not then be actually delivered to Holder. In case Holder shall exercise this Warrant
with respect to fewer than all of the shares that may be purchased under this Warrant, the Company shall execute a new
warrant in the form of this Warrant for the balance of such shares and deliver such new warrant to Holder.

 

     

     

    

 

(c)      Duration. This Warrant shall
expire at the close of business on the earlier to occur of (i) the three-year anniversary of the initial closing date under
the Stock Purchase Agreement; (ii) 10 days immediately following the occurrence of an Early Termination Trigger; (iii) a
Deemed Liquidation Event (as defined in the Amended and Restated Certificate of Incorporation of the Company, as hereafter amended
and/or restated); or (iv) the liquidation of the Company pursuant to a Plan of Complete Liquidation. An “Early Termination
Trigger” will occur if, for at least 10 days out of any consecutive 20-day period after the one-year anniversary of an initial
public offering of the Company’s Common Stock, the closing sales price of the Common Stock on the securities exchange on
which the Common Stock is listed is at least $4.50 per share (subject to adjustment for stock splits, recapitalizations and combinations
and similar events with respect to the capital stock of the Company).

 

Section 2.         Reservation of Shares.
The Company hereby agrees that at all times, there shall be reserved for issuance and delivery upon exercise of this Warrant
such number of shares of Preferred Stock from time to time issuable upon exercise of this Warrant and such number of shares of
Common Stock into which those shares are convertible.

 

Section 3.         Covenants as to
Capital Stock. The Company covenants and agrees that all shares of Preferred Stock that may be issued upon the exercise
of the rights represented by this Warrant, and all shares of Common Stock into which those shares are convertible, will, upon
issuance, be validly issued, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the
issue thereof. Without limiting the generality of the foregoing, the Company covenants that it will from time to time take
all such other action as may be required to assure that the stated or par value per share of the Preferred Stock is at all
times equal to or less than the then-effective Warrant Price per share of the Preferred Stock issuable upon exercise of this
Warrant.

 

Section 4.         Adjustments.

 

(a)       Stock Split, Subdivision or Combination.
If the Company, at any time while this Warrant is outstanding, shall split, subdivide or combine the Preferred Stock (by reclassification
or otherwise than by payment of a dividend in Preferred Stock), the number of shares subject to purchase under this Warrant (i) shall
be proportionately increased and the Warrant Price shall be proportionately decreased, in case of a split or subdivision of Preferred
Stock, as of the effective date of such stock split or subdivision, or, if the Company shall take a record of the holders of the
Preferred Stock for the purpose of so splitting or subdividing, as at such record date, whichever is earlier, or (ii) shall
be proportionately decreased and the Warrant Price per share shall be proportionately increased, in the case of combination of
Preferred Stock, as at the effective date of such combination or, if the Company shall take a record of holders of the Preferred
Stock for the purpose of so combining, as at such record date, whichever is earlier.

 

     

     

    

 

(b)      Stock Dividends. In the
event the Company, at any time or from time to time while this Warrant is outstanding, shall pay a dividend payable in, or
make any other distribution (except any distribution specifically provided for in Section 4(a) or
Section 4(c) hereof) in the nature of a dividend of, the Preferred Stock, then the Warrant Price shall be adjusted,
from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price
determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction, the
numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or
distribution, and the denominator of which shall be the total number of shares of Preferred Stock outstanding immediately
after such dividend or distribution. Holder shall thereafter be entitled to purchase, at the Warrant Price resulting from
such adjustment, the number of shares of Preferred Stock (calculated to the nearest whole share) obtained by multiplying the
Warrant Price in effect immediately prior to such adjustment by the number of shares of Preferred Stock issuable upon the
exercise hereof immediately prior to such adjustment, and dividing the product so obtained by the Warrant Price resulting
from such adjustment.

 

(c)      Asset or Capital Dividend. If
the Company, at any time while this Warrant is outstanding, shall make a distribution of its assets to the holders of the
Preferred Stock and/or any class of stock convertible into the Preferred Stock as a dividend in liquidation or partial
liquidation or as a return of capital other than as a dividend payable out of funds legally available for dividends under the
laws of the State of Delaware, Holder shall, upon exercise and payment of the Warrant Price within 14 business days after
notification of such distribution pursuant to Section 11 below, be entitled to receive, in addition to the number of
shares receivable thereupon, and without payment of any additional consideration therefor, a sum equal to the amount of such
assets as would have been payable to Holder had Holder been the holder of record of such shares on the record date for such
distribution; and an appropriate provision therefor shall be made for Holder to be made a party to any such distribution.

 

(d)      Adjustments for
Consolidation, Merger, Sale of Assets, Reorganization or Reclassification. Subject to the provisions of
Section 1(d) hereof, in the event the Company, at any time or from time to time while this Warrant is outstanding,
(i) shall consolidate with or merge into any other entity and shall not be the continuing or surviving corporation of
such consolidation or merger; (ii) shall permit any other entity to consolidate with or merge into the Company and the
Company shall be the continuing or surviving entity but, in connection with such consolidation or merger, the Preferred Stock
shall be changed into or exchanged for capital stock or other securities or property of any other entity; (iii) shall
transfer all or substantially all of its properties and assets to any other entity or (iv) shall effect a capital
reorganization or reclassification of the Preferred Stock (other than one deemed to result in the issue of additional
Preferred Stock), then, and in each such event, lawful provision shall be made so that Holder shall be entitled to receive
upon the exercise hereof at any time after the consummation of such consolidation, merger, transfer, reorganization or
reclassification, in lieu of the shares issuable upon exercise of this Warrant prior to such consummation, the capital stock
and other securities and property to which Holder would have been entitled upon such consummation if Holder had exercised
this Warrant immediately prior thereto.

 

(e)       Certificate of Adjustment. The
Company shall, within a reasonable time period after written request at any time by Holder, furnish or cause to be furnished to
Holder a certificate setting forth adjustments of the Warrant Price and of the number of shares issuable upon exercise of this
Warrant and the amount, if any, of other property at the time receivable upon the exercise of this Warrant.

 

     

     

    

 

(f)       No Other Adjustment. The
amount of Shares subject to purchase under this Warrant and the Warrant Price shall not be adjusted except in the manner and upon
the terms and conditions set forth in Section 4 of this Warrant.

 

Section 5.         Transfer of Warrant.
This Warrant and all rights hereunder are transferable, subject to compliance with the registration provisions or exemptions
therefrom under the federal securities laws and applicable state law, in whole or in part at the office of the Company by Holder
in person or by duly authorized attorney, upon surrender of this Warrant properly endorsed. Each taker and holder of this Warrant,
by taking or holding the same, consents and agrees that this Warrant, when so endorsed in blank, shall be deemed negotiable, and,
when so endorsed such holder hereof may be treated by the Company and all other persons dealing with this Warrant as the absolute
owner hereof for any purposes and as the person entitled to exercise the rights represented by this Warrant, or to the transfer
hereof on the books of the Company, any notice to the contrary notwithstanding; but until each such transfer on such books, the
Company may treat the registered holder hereof as the owner hereof for all purposes.

 

Section 6.          Exchange of
Warrant. This Warrant is exchangeable, upon the surrender hereof by Holder at the office of the Company for new Warrants
of like tenor representing in the aggregate the rights to subscribe for and purchase the number of shares that may be
subscribed for and purchased hereunder, each of such new Warrants to represent the right to subscribe for and purchase such number
of shares as shall be designated by Holder at the time of such surrender.

 

Section 7.          Fractional Shares. Fractional
shares shall not be issued upon the exercise of this Warrant, but in any case where Holder would, except for the provisions
of this Section 7, be entitled under the terms hereof to receive a fraction of a share upon the exercise of this
Warrant, the Company shall, upon the exercise of this Warrant, pay a sum in cash equal to the product obtained by multiplying
such fraction by the Current Fair Market Value of Preferred Stock. As used herein, “Current Fair Market Value”
shall mean with respect to each share of Preferred Stock the fair market value per share as determined in good faith by the
Board of Directors of the Company with reference to the valuation used in the Company Sale, unless the Holder shall purchase
such shares in conjunction with an underwritten public offering of the Company’s Common Stock pursuant to a
registration statement filed under the Securities Act of 1933, as amended, in which case the Current Fair Market Value shall
be based upon the price at which the Common Stock is sold to the public in such offering.

 

Section 8.         Lost, Stolen, Mutilated
or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity
or otherwise as it may in its discretion impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant
shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed
Warrant shall be at any time enforceable by anyone.

 

Section 9.         No Stockholder
Rights. This Warrant shall not entitle Holder to any rights as a stockholder of the Company. To the extent that Holder is
not at the time of exercise of this Warrant a stockholder of the Company, as a condition to the exercise hereof, Holder shall
execute an agreement to be bound by any then-effective stockholders agreement, registration rights agreement and/or any
agreement to which the holders of Preferred Stock of the Company are parties.

 

     

     

    

 

 

Section 10. Amendments and Waivers.
The Warrants, including this Warrant, may be amended, modified or supplemented, and waiver or consents to departures from the

 

provisions of the Warrants may be given, if the Company and
the holders of at least a majority of the shares of Series A Preferred Stock of the Company for which the Warrants are exercisable
consent to such amendment, modification, supplement, waiver or consent. Such consent may be effected by any available legal means,
including, without limitation, at a special or regular meeting, by written consent or otherwise. Notwithstanding anything to the
contrary contained herein, any provision of this Warrant may also be amended, modified or supplemented, and waivers or consents
to departures hereof may be given, the result of which shall not adversely affect any other holder of the Warrants, upon the written
agreement of the Company and Holder. Any amendment, modification, supplement or waiver effected in accordance with this Section 10
shall apply to and be binding upon Holder, each future holder of this Warrant and the Company, whether or not this Warrant shall
have been marked to indicate such amendment, modification, supplement or waiver. No such amendment, modification, supplement or
waiver shall extend to or affect any obligation not expressly amended, modified, supplemented or waived or impair any right consequent
thereon.

 

Section 11. Notices. All notices
given hereunder shall be in writing and shall be delivered in person or duly sent by mail, postage prepaid; by an overnight delivery
service, charges prepaid; or by confirmed facsimile; addressed to Holder at his or her address in the records of the Company and
addressed to the Company at its principal place of business to the attention of its Secretary.

 

Section 12.
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, notwithstanding
principles of conflicts of laws.

 

     

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its duly authorized officer as of the date first written above.

 

		IMMUNOME, INC.
	 	 
		By:	 
	 	 	Purnanand Sarma
		 	Chief Executive Officer and President

 

     

     

    

 

FORM OF SUBSCRIPTION

 

The undersigned, the holder of the
within Warrant, hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to purchase
thereunder,                           
               
(                                )
shares of Series A Preferred Stock of Immunome, Inc. covered by Warrant
No. A-          according to the conditions thereof, and requests that
the certificate(s) for such shares be issued in the name of, and delivered to, the undersigned.

 

Such exercise is made pursuant to
Section 1(a) of the within Warrant and the undersigned herewith makes payment of the Warrant Price for such shares
in full in the amount of $                 .

 

	Dated:	 	 	 
		 	 	Signature of Warrant Holder
	 	 	 	 
		 	 	Name of Warrant Holder (Please Print)
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	(Address)

 

    

     

    

 

FORM OF ASSIGNMENT

 

For value received, the undersigned
hereby sells, assigns and transfers unto                           ,
all of the rights represented by the within Warrant to purchase                           shares
of Series A Preferred Stock of Immunome, Inc. to which the within Warrant relates, and appoints                      
attorney to transfer such right on the books of Immunome, Inc. with full power of substitution in the premises.

 

	Dated:	 	 	 
		 	 	Signature of Warrant Holder
	 	 	 	 
		 	 	Name of Warrant Holder (Please Print)
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	(Address)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]